ICYMI: Good Results From Evinacumab for Rare Form of Familial Hypercholesterolemia
A press release issued recently by Regeneron Pharmaceuticals heralded the acceptance of a Biologics License Application by the FDA for Priority Review of its investigational drug, evinacumab. The Priority…